
The combination of cefepime with boronic acid transition state inhibitors (BATSIs) S02030 and MB076 shows potent antimicrobial activity against Enterobacterales expressing class A and C β-lactamases, including KPC. In vitro and in vivo studies demonstrate bactericidal effects against KPC-producing Klebsiella pneumoniae (KPC-Kpn-1), with MB076 enhancing the efficacy of cefepime. These findings support the continued development of cefepime-MB076 as a promising treatment for KPC-producing infections.
Like
Save
Share